

# Pavel Strop

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1770758/publications.pdf>

Version: 2024-02-01

28  
papers

1,751  
citations

516215

16  
h-index

476904

29  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1928  
citing authors

#	ARTICLE	IF	CITATIONS
1	Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model. <i>Scientific Reports</i> , 2022, 12, 3530.	1.6	5
2	Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies. <i>Bioconjugate Chemistry</i> , 2022, 33, 576-585.	1.8	5
3	Cancer Immunotherapy and the Nectin Family. <i>Annual Review of Cancer Biology</i> , 2021, 5, 203-219.	2.3	14
4	Structures of mouse and human GITR-GITRL complexes reveal unique TNF superfamily interactions. <i>Nature Communications</i> , 2021, 12, 1378.	5.8	10
5	Automated and Faster Affinity Capture Method for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates. <i>Analytical Chemistry</i> , 2021, 93, 5371-5376.	3.2	9
6	Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 354-369.	2.6	37
7	Antibody blockade of CD96 by distinct molecular mechanisms. <i>MAbs</i> , 2021, 13, 1979800.	2.6	2
8	High-Throughput Surface Plasmon Resonance Biosensors for Identifying Diverse Therapeutic Monoclonal Antibodies. <i>Analytical Chemistry</i> , 2021, 93, 16474-16480.	3.2	7
9	Universal Affinity Capture Liquid Chromatography-Mass Spectrometry Assay for Evaluation of Biotransformation of Site-Specific Antibody Drug Conjugates in Preclinical Studies. <i>Analytical Chemistry</i> , 2020, 92, 2065-2073.	3.2	19
10	Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models. <i>MAbs</i> , 2020, 12, 1685350.	2.6	19
11	High-Throughput Platform to Identify Antibody Conjugation Sites from Antibody-Drug Conjugate Libraries. <i>Bioconjugate Chemistry</i> , 2020, 31, 1199-1208.	1.8	5
12	Integrated Approach for Characterizing Bispecific Antibody/Antigens Complexes and Mapping Binding Epitopes with SEC/MALS, Native Mass Spectrometry, and Protein Footprinting. <i>Analytical Chemistry</i> , 2020, 92, 10709-10716.	3.2	14
13	Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer. <i>Scientific Reports</i> , 2019, 9, 8420.	1.6	41
14	Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates. <i>Scientific Reports</i> , 2019, 9, 2443.	1.6	15
15	RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models. <i>Oncotarget</i> , 2018, 9, 33446-33458.	0.8	15
16	Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates. <i>Bioconjugate Chemistry</i> , 2017, 28, 1102-1114.	1.8	35
17	Antibodies Targeting Closely Adjacent or Minimally Overlapping Epitopes Can Displace One Another. <i>PLoS ONE</i> , 2017, 12, e0169535.	1.1	32
18	Engineering Highly Potent and Selective Microproteins against Nav1.7 Sodium Channel for Treatment of Pain. <i>Journal of Biological Chemistry</i> , 2016, 291, 13974-13986.	1.6	44

#	ARTICLE	IF	CITATIONS
19	RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2698-2708.	1.9	78
20	Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 958-970.	1.9	141
21	Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates. <i>Bioconjugate Chemistry</i> , 2015, 26, 650-659.	1.8	112
22	Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. <i>Nature Biotechnology</i> , 2015, 33, 694-696.	9.4	118
23	Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy. <i>PLoS ONE</i> , 2015, 10, e0132282.	1.1	47
24	Mass Spectrometric Characterization of Transglutaminase Based Site-Specific Antibody-Drug Conjugates. <i>Bioconjugate Chemistry</i> , 2014, 25, 240-250.	1.8	56
25	Versatility of Microbial Transglutaminase. <i>Bioconjugate Chemistry</i> , 2014, 25, 855-862.	1.8	149
26	Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates. <i>Chemistry and Biology</i> , 2013, 20, 161-167.	6.2	412
27	Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9. <i>Journal of Biological Chemistry</i> , 2012, 287, 11090-11097.	1.6	157
28	Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair. <i>Journal of Molecular Biology</i> , 2012, 420, 204-219.	2.0	148